ACADIA Pharmaceuticals Inc. Stock price

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
18.49 USD +1.59% Intraday chart for ACADIA Pharmaceuticals Inc. +0.43% -40.95%
Sales 2024 * 968M Sales 2025 * 1.1B Capitalization 3B
Net income 2024 * 112M Net income 2025 * 219M EV / Sales 2024 * 2.47 x
Net cash position 2024 * 606M Net cash position 2025 * 863M EV / Sales 2025 * 1.95 x
P/E ratio 2024 *
27.8 x
P/E ratio 2025 *
14.1 x
Employees 598
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.48%
More Fundamentals * Assessed data
Dynamic Chart
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating MT
Transcript : ACADIA Pharmaceuticals Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 02:00 PM
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept MT
North American Morning Briefing : Stock Futures -2- DJ
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Gain Premarket Tuesday MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating MT
More news
1 day-0.69%
1 week-1.14%
Current month-21.69%
1 month-23.35%
3 months-42.01%
6 months-15.47%
Current year-41.87%
More quotes
1 week
17.56
Extreme 17.56
18.39
1 month
17.56
Extreme 17.56
24.53
Current year
17.56
Extreme 17.56
31.82
1 year
17.56
Extreme 17.56
33.99
3 years
12.24
Extreme 12.24
33.99
5 years
12.24
Extreme 12.24
58.72
10 years
12.24
Extreme 12.24
58.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 14-07-14
Director of Finance/CFO 50 20-05-27
Chief Tech/Sci/R&D Officer - 21-02-28
Members of the board TitleAgeSince
Director/Board Member 57 15-12-10
Director/Board Member 71 15-11-24
Chief Executive Officer 63 14-07-14
More insiders
Date Price Change Volume
24-03-28 18.49 +1.59% 1 481 512
24-03-27 18.2 +2.30% 1,701,367
24-03-26 17.79 -0.28% 1,445,409
24-03-25 17.84 -0.61% 1,845,162
24-03-22 17.95 -2.50% 1,480,951

Delayed Quote Nasdaq, March 28, 2024 at 10:05 am EDT

More quotes
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
18.2 USD
Average target price
29.31 USD
Spread / Average Target
+61.04%
Consensus
  1. Stock
  2. Equities
  3. Stock ACADIA Pharmaceuticals Inc. - Nasdaq